12.5mg Zepbound (tirzepatide) injection pen and vial

12.5mg Zepbound (tirzepatide) injection pen and vial

This site is intended for U.S. Healthcare Providers

Explore Zepbound®(tirzepatide) injection
Dosing

true
Find information about starting and maintenance dosages for your patients on Zepbound.

2.5 mg is a starting dose and is not an approved maintenance dose.
true
on this page

Dosing options

Dosing Options

DosingOptions

Dosing schedule

Dosing Schedule

DosingSchedule

Mitigating gastrointestinal side effects

Mitigating Gastrointestinal Side Effects

MitigatingSideEffects

Missed dose

Missed Dose

MissedDose

backgroundOption
image
backgroundColor
primary
image
Gradient background
textColor
auto

EXPLORE DOSING

Explore dosing options for Zepbound
text
DosingOptions
backgroundOption
color
backgroundColor
background-none
textColor
auto
additionalPadding
narrow
Zepbound Single-Dose Pen
zepbound_pen_section
Zepbound Single-Dose Vial
zepbound_vial_section
Zepbound® KwikPen® for Single-Patient Use
zepbound_kwikpen_section
style
tabs-container-background-none
Zepbound (tirzepatide) injection pen
2.5 mg is for treatment initiation only
Zepbound Single-Dose Pen
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg

Share the savings card for the Single-Dose Pen with your eligible, commercially insured patients.
Share the Zepbound savings card
Prescribe via LillyDirect®
Governmental beneficiaries excluded, terms and conditions apply. Review full terms and conditions
text
zepbound_pen_section
backgroundOption
color
backgroundColor
background-none
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
Zepbound (tirzepatide) injection KwikPen
2.5 MG IS FOR TREATMENT INITIATION ONLY
Zepbound® KwikPen® for Single-Patient Use

2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (4 doses per KwikPen)

For patients, regardless of insurance, including Medicare, Medicaid, and no insurance. Terms apply. Taxes and fees may apply.


LillyDirect®

Available through LillyDirect® Pharmacy with automatic self-pay pricing applied.

Retail Pharmacies

If patient chooses to fulfill their KwikPen prescription at a retail pharmacy, they can use the self-pay savings card at zepbound.com/savings


Self-pay only. Eligibility required, terms and conditions apply. Savings subject to monthly and annual limits. Month is defined as 28-days and 1 single-patient-use KwikPen. Card eligibility and terms and conditions may be terminated, rescinded, revoked, or amended by Lilly at any time without notice and for any reason. PROGRAM IS NOT INSURANCE. Review full terms and conditions at: https://zepbound.lilly.com/savings#terms-and-conditions-2

Prescribe via LillyDirect®
text
zepbound_kwikpen_section
backgroundOption
color
backgroundColor
background-none
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
Zepbound (tirzepatide) injection vial
2.5 mg is for treatment initiation only
Zepbound Single-Dose Vial
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg

For patients, regardless of insurance, including Medicare, Medicaid, and no insurance

Available exclusively through LillyDirect® Pharmacy. Terms apply. Taxes and fees may apply.
Prescribe via LillyDirect®
text
zepbound_vial_section
backgroundOption
color
backgroundColor
background-none
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto

Have questions about the cost and coverage for Zepbound?

See the savings
backgroundOption
color
backgroundColor
background-muted
textColor
auto
additionalPadding
narrow
additionalMargin
narrow
roundedBorders
true

DOSING SCHEDULE

Starting and continuing Zepbound

A once-weekly, subcutaneous injection1
text
DosingSchedule
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
Start and continue once-weekly Zepbound
Start and continue once-weekly Zepbound

Show Description

Image depicting the dose escalation of Zepbound. Starting dose is 2.5 mg once weekly for 4 weeks. Continue to 5 mg dose once weekly for at least 4 weeks. The dose can be increased to 7.5 mg once weekly for at least 4 weeks, followed by 10 mg maintenance dose once weekly for at least 4 weeks, then 12.5 mg once weekly for at least 4 weeks, and finally 15 mg maintenance dose once weekly as the maximum dose. 5 mg is a recommended maintenance dose for weight reduction indication only; 10 mg or 15 mg are recommended maintenance doses for all approved indications.

true
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
none

For adults with obesity, or with overweight with at least 1 weight-related comorbidity in combination with a reduced-calorie diet and increased physical activity.1

For adults with moderate-to-severe OSA and obesity in combination with a reduced-calorie diet and increased physical activity.1

The 2.5 mg dosage is for treatment initiation and is not intended to be a maintenance dose.1

Recommended maintenance dosages are 5 mg, 10 mg, or 15 mg for weight reduction and 10 mg or 15 mg for moderate-to-severe OSA and obesity1

  • Initiate with the 2.5 mg dose
  • After 4 weeks, increase to the 5 mg dose
  • You can continue to increase the dose by 2.5 mg increments after at least 4 weeks on the current dose. The maximum dose is 15 mg
  • Consider treatment response and tolerability when selecting maintenance dosage. If not tolerated, consider a lower maintenance dosage
backgroundOption
color
backgroundColor
background-custom
textColor
auto
style
two-col-50-50, inner-color
additionalPadding
none
additionalMargin
none
OSA=obstructive sleep apnea.
backgroundOption
color
backgroundColor
background-custom
textColor
auto
Ways you can help your
patients:

01

numeric-tile, title-fs-36px, texttitle-fs-32px, description-fs-20px

Remind

Patients that Zepbound is administered once weekly.1

02

numeric-tile, title-fs-36px, texttitle-fs-32px, description-fs-20px

Advise

Patients to read the Instructions for Use.2

03

numeric-tile, title-fs-36px, texttitle-fs-32px, description-fs-20px

Consider

Having patients administer the first dose in the office.

04

numeric-tile, title-fs-36px, texttitle-fs-32px, description-fs-20px

Discuss

Safety profile and that Zepbound may cause some side effects.* For example, patients may experience nausea, diarrhea, or vomiting.1

Mitigate gastrointestinal side effects

In order to mitigate gastrointestinal side effects, patients may find it helpful to3-5:
Eating smaller meals icon

Eat smaller meals

tile, title-fs-28px, description-fs-16px, ctaselection-link
Suggest that they split 3 daily meals into 4 or more smaller meals
feeling full icon

Stop eating when they feel full

tile, title-fs-28px
hamburger icon

Avoid fatty foods

tile, title-fs-28px
toast icon

Try eating bland foods

tile, title-fs-28px
medicin bottle icon

Drink plenty of water

tile, title-fs-28px, description-fs-16px
Encourage patients to eat healthy meals to ensure they meet their needs for protein, micronutrients, fiber, and fluids.
*Side effects may vary and should be evaluated by the healthcare provider for appropriate management.
water bottle icon

Recommend switching to non-oral contraceptive

tile, title-fs-28px, description-fs-16px
Recommend patients who are using oral hormonal contraceptives switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with Zepbound and for 4 weeks after each dose escalation. Use of Zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time.1
text
MitigatingSideEffects
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
DOSING SCHEDULE

What happens if a dose is missed?

If a dose is missed, instruct patients to administer Zepbound as soon as possible within 4 days after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day.1
For adult patients with obesity (BMI of ≥30 kg/m2) or with overweight (BMI of ≥27 kg/m2) with at least 1 weight-related comorbidity.1
dosing schedule image
dosing schedule image
true
Shield with exclamation point inside
Select Important Safety Information
Severe Gastrointestinal Adverse Reactions: Use of Zepbound has been associated with gastrointestinal adverse reactions, sometimes severe. In a pool of two Zepbound clinical trials (SURMOUNT-1 and SURMOUNT-2), severe gastrointestinal adverse reactions were reported more frequently among patients receiving Zepbound (5 mg 1.7%, 10 mg 2.5%, 15 mg 3.1%) than placebo (1.0%). Similar rates of severe gastrointestinal adverse reactions were observed in Zepbound clinical trials for weight reduction and in Zepbound clinical trials for obstructive sleep apnea (OSA). Severe gastrointestinal adverse reactions have also been reported postmarketing with GLP-1 receptor agonists. Zepbound is not recommended in patients with severe gastroparesis.
text
MissedDose
backgroundOption
color
backgroundColor
background-none
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
additionalMargin
none
Helpful resources for you
Discover how you can help your patients by completing prior authorization, ordering a demo kit, or learning about a savings card.
Explore all resources
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
additionalMargin
none

AUTHORIZATION GUIDE

Get the Prior Authorization Guide
A guide on how to complete a prior authorization.
Download guide

SAVINGS CARD

Share the Zepbound savings card for the Single-Dose Pen
Download a savings card for your eligible, commercially insured patients with Zepbound coverage.

Governmental beneficiaries excluded, terms and conditions apply. Review full terms and conditions
Learn more
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
style
two-col-50-50, inner-color
additionalPadding
narrow
additionalMargin
none
backgroundOption
color
backgroundColor
background-custom
textColor
auto
backgroundOption
color
backgroundColor
background-custom
textColor
auto
Pharmacist working in a pharmacy

Start your patients on Zepbound

Learn more
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
additionalMargin
none

References

  1. Zepbound. Prescribing Information. Lilly USA, LLC.
  2. Zepbound. Instructions for Use. Lilly USA, LLC.
  3. Maceira E, Lesar TS, Smith HS. Medication related nausea and vomiting in palliative medicine. Ann Palliat Med. 2012;1(2):161-176. doi:10.3978/j.issn.2224-5820.2012.07.11
  4. Kruger DF, Bode B, and Spollett GR. Understanding GLP-1 analogs and enhancing patients success. Diabetes Educ. 2010;36(suppl 3):S44-S74. doi:10.1177/0145721710374370
  5. Reid TS. Practical use of glucagon-like peptide-1 receptor agonist therapy in primary care. Clin Diabetes. 2013;31(4):148-157. doi:10.2337/diaclin.31.4.148
backgroundOption
color
backgroundColor
background-custom
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow
Chats

Call Us

tile, ctaselection-link, ctatarget-sametab, ctaexitinterstitial-select
Dial 1-800-LillyRx
(1-800-545-5979) to contact Lilly Support Services
CMAT-22252 05/2026 © Lilly USA, LLC 2026. All rights reserved.
backgroundOption
color
backgroundColor
background-premium
desktopBackgroundImagePositioning
center center
mobileBackgroundImagePositioning
center center
textColor
auto
additionalPadding
narrow